The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

post
The Startup’s Guide: 10 Must-Have CMC SOPs for Virtual Pharma in Phase 1
Read More

white-paper
The CMC Trap: How Chemistry, Manufacturing, and Controls Failures Derail Drug Development
Read More

post
FDA PreCheck Pilot: A Smarter, Infrastructure-Centered Alternative to Fast Track and Breakthrough Designations
Read More

infographic
The Business Case for Investing in CMC: Protecting Your Asset and Ensuring Success
Read More
Let's move from science to success.
Let’s Talk